EGFR and non-small cell lung carcinoma: Importantly, the IMpower150 trial reported that in EGFR-mutant NSCLC patients the addition of Atezolizumab to Bevacizumab plus carboplatin plus paclitaxel (ABCP) provided significant clinical benefit (41).